{
    "nctId": "NCT04778982",
    "briefTitle": "Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer",
    "officialTitle": "A Phase II Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Locally Advanced HER2-positive Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "HER2-positive Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 4,
    "primaryOutcomeMeasure": "Dose limiting toxicity (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female subject \\>= 18 years;\n* Histologically or cytologically confirmed, metastatic or locally advanced unresectable HER2-positive;\n* Adequate organ function assessed within 7 days prior to first trial treatment\n* ECOG score 0 or 1;\n* Left ventricular ejection fraction (LVEF) \u2265 50% at baseline;\n* Life expectancy \\>3 months\n\nExclusion Criteria:\n\n* Untreated active CNS metastasis or leptomeningeal metastasis;\n* Uncontrolled tumor-related pain;\n* Has received other anti-tumor treatment or an investigational drug within 28 days or within 5 times of half-life (whichever is shorter, and no less than 2 weeks) prior to the first trial treatment;\n* Major surgery for any reason within 28 days;\n* Curative radiation within 3 months of the first dose of trial treatment;\n* History of uncontrolled intercurrent illness;\n* Other medical conditions that at the discretion of investigator interfere with the requirements of the trial in terms of safety or efficacy evaluation, or treatment compliance",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}